Early H1N1 Flu Wave Hits U.S. Ahead of Peak
Adults 50 and older can ask a doctor now whether the new mRNA flu vaccine fits their plans this season.
Updated on Nov. 2, 2026 in COVID-19

Live Poll
Do you plan to get your flu and COVID-19 vaccines this season?
An early influenza wave driven by a mutated H1N1 strain is underway in the United States during the 2026 respiratory season. The CDC reported almost 5,000 laboratory-confirmed flu hospitalizations nationwide in the week ending Oct. 17, the highest early-season mid-October rate since 2010-2011.
Why it matters
The H1N1 variant carries new mutations compared with last year's virus, which causes some mismatch with the current vaccine and is why this early wave is drawing attention. For adults, especially those 50 and older, the timing makes this a practical moment to think about flu protection before peak season.
CDC surveillance data for the week ending Oct. 17 document almost 5,000 lab-confirmed flu hospitalizations nationwide, and H1N1 made up 125 of 127 subtyped influenza A viruses in the week ending Oct. 3. Preliminary data indicate the current vaccine's antibodies recognize the new variant, but full vaccine efficacy estimates are still pending.
The players
Centers for Disease Control and Prevention (CDC)
The U.S. federal agency that tracks influenza and other respiratory illness through national surveillance and issues public health guidance.
Johns Hopkins University
A research university whose medical researchers study infectious diseases, including influenza, COVID-19 and RSV.
The details
Influenza A viruses are subtyped, and in recent surveillance H1N1 has dominated. The new variant has picked up mutations relative to last year's virus, which can change how well immune responses built by the current vaccine match it. Vaccines are monitored through passive surveillance, in which anyone can report an adverse event to the Vaccine Adverse Event Reporting System, and through active surveillance run by health care systems and other networks that search for cases.
Timeline
Week ending Oct. 3: H1N1 accounted for 125 of 127 subtyped flu A viruses in CDC surveillance.
Week ending Oct. 17: Almost 5,000 lab-confirmed flu hospitalizations were reported nationwide.
Oct. 29: Johns Hopkins media briefing with Pekosz and Durbin.
Early December: Early flu vaccine efficacy estimates are expected.
December and January: A COVID-19 surge is expected.
Health Landscape
The CDC's weekly influenza surveillance is the benchmark against which this season's early hospitalization rate is measured, and the mid-October figure is the highest since 2010-2011. The mRNA influenza vaccine, licensed for people 50 and older, adds a newer option to a landscape long dominated by traditional flu vaccines.
If you are 50 or older, this is a good time to ask your doctor whether the licensed mRNA flu vaccine or another flu vaccine is right for you before the season peaks. Because mild side effects such as body aches and a low-grade fever are possible, it is worth knowing what to expect and discussing any questions with your clinician.
The takeaway
Flu activity is running early and H1N1 is the dominant strain, so flu protection is worth thinking about now rather than later. Home tests can distinguish influenza, COVID-19 and RSV, so if symptoms appear, a quick test can help you and your doctor decide on next steps.
What happens next
Early efficacy estimates for the influenza vaccine should come in early December, and a COVID-19 surge is expected in December and January.
Further reading
For broader context on respiratory viruses circulating alongside flu, see COVID-19 coverage on We are Healthy.
Source note: This article includes information reported by Infection Control Today.
Live Poll
Do you plan to get your flu and COVID-19 vaccines this season?





